e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses
Troy Lauren K., Corte Tamera J.
Source:
Eur Respir J 2016; 47: 27-30
Journal Issue:
January
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Troy Lauren K., Corte Tamera J.. Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses. Eur Respir J 2016; 47: 27-30
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay.
The cryoTBB role in the diagnostic work-up of IPF: an European perspective; emergent standardization guidelines
Acute exacerbations of IPF: A neglected threat in IPF ?
Related content which might interest you:
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
Source: Eur Respir J 2016; 47: 243-253
Year: 2016
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Management of idiopathic pulmonary fibrosis: selected case reports
Source: Eur Respir Rev 2014; 23:239-248
Year: 2014
Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg).
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation
Source: Eur Respir Rev 2015; 24: 436-444
Year: 2015
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Survival in idiopathic pulmonary fibrosis: results of the IFIGENIA follow up study
Source: Eur Respir J 2004; 24: Suppl. 48, 254s
Year: 2004
Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP)
Source: International Congress 2014 – IPF and surroundings
Year: 2014
Does early diagnosis of idiopathic pulmonary fibrosis matter? Real- world´s data from the EMPIRE registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP)
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Severe idiopathic pulmonary fibrosis: what can be done?
Source: Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017
Year: 2017
Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward
Source: Eur Respir J 2013; 42: 1446-1448
Year: 2013
Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Nutritional assessment in patients with idiopathic pulmonary fibrosis: the NUTRIPF study
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Idiopathic pulmonary fibrosis trials: recommendations for the jury
Source: Eur Respir J 2011; 38: 1002-1004
Year: 2011
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept